BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 36721777)

  • 1. Next-generation sequencing shows the genomic features of ovarian clear cell cancer and compares the genetic architectures of high-grade serous ovarian cancer and clear cell carcinoma in ovarian and endometrial tissues.
    Gan M; Tai Z; Yu Y; Zhang C; Xu J
    PeerJ; 2023; 11():e14653. PubMed ID: 36721777
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular portraits of clear cell ovarian and endometrial carcinoma with comparison to clear cell renal cell carcinoma.
    Ackroyd SA; Arguello D; Ramos P; Mahdi H; ElNaggar A; Winer I; Holloway R; Krivak T; Jones N; Turner VG; Herzog T; Chu C; Brown J; Mantia-Smaldone G
    Gynecol Oncol; 2023 Feb; 169():164-171. PubMed ID: 36333181
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genomic profiling of ovarian clear cell carcinoma in Chinese patients reveals potential prognostic biomarkers for survival.
    Ye S; Zhou S; Wu Y; Pei X; Jiang W; Shi W; Yang W; Zhou X; Shan B; Yang H
    Ann Med; 2023 Dec; 55(1):2218104. PubMed ID: 37272300
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distinct gene expression profiles associated with clinical outcomes in patients with ovarian clear cell carcinoma and high-grade serous ovarian carcinoma.
    Zhou H; Liu Q; Shi X; Liu Y; Cao D; Yang J
    J Ovarian Res; 2020 Apr; 13(1):38. PubMed ID: 32295618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genomic landscape of ovarian clear cell carcinoma via whole exome sequencing.
    Kim SI; Lee JW; Lee M; Kim HS; Chung HH; Kim JW; Park NH; Song YS; Seo JS
    Gynecol Oncol; 2018 Feb; 148(2):375-382. PubMed ID: 29233531
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of somatic genetic alterations in ovarian clear cell carcinoma with next generation sequencing.
    Shibuya Y; Tokunaga H; Saito S; Shimokawa K; Katsuoka F; Bin L; Kojima K; Nagasaki M; Yamamoto M; Yaegashi N; Yasuda J
    Genes Chromosomes Cancer; 2018 Feb; 57(2):51-60. PubMed ID: 29044863
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The clinical characteristics and outcomes of cases with pure ovarian clear cell, mixed type and high-grade serous adenocarcinoma.
    Kucukgoz Gulec U; Paydas S; Guzel AB; Vardar MA; Khatib G; Gumurdulu D
    Arch Gynecol Obstet; 2015 Oct; 292(4):923-9. PubMed ID: 25855053
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted sequencing of a specific gene panel detects a high frequency of ARID1A and PIK3CA mutations in ovarian clear cell carcinoma.
    Su YF; Tsai EM; Chen CC; Wu CC; Er TK
    Clin Chim Acta; 2019 Jul; 494():1-7. PubMed ID: 30851247
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the clinical characteristics and prognosis between clear cell carcinomas and high-grade serous ovarian carcinomas.
    Dong S; Yu F; Liu Y; Yu X; Sun X; Wang W; Wang Y
    Ginekol Pol; 2023; 94(10):792-798. PubMed ID: 36477777
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular evidence for a clonal relationship between synchronous uterine endometrioid carcinoma and ovarian clear cell carcinoma: a new example of "precursor escape"?
    Weng CH; Wu RC; Chen SJ; Chen HC; Tan KT; Lee YS; Huang SS; Yang LY; Wang CJ; Chou HH; Chao AS; Chao A; Lai CH
    J Mol Med (Berl); 2021 Jul; 99(7):959-966. PubMed ID: 33768299
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of novel mutations in Japanese ovarian clear cell carcinoma patients using optimized targeted NGS for clinical diagnosis.
    Maru Y; Tanaka N; Ohira M; Itami M; Hippo Y; Nagase H
    Gynecol Oncol; 2017 Feb; 144(2):377-383. PubMed ID: 27939411
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current and future strategies for treatment of ovarian clear cell carcinoma.
    Ogasawara A; Sato S; Hasegawa K
    J Obstet Gynaecol Res; 2020 Sep; 46(9):1678-1689. PubMed ID: 32578333
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutational status of KRAS, NRAS, and BRAF in primary clear cell ovarian carcinoma.
    Zannoni GF; Improta G; Chiarello G; Pettinato A; Petrillo M; Scollo P; Scambia G; Fraggetta F
    Virchows Arch; 2014 Aug; 465(2):193-8. PubMed ID: 24889043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genomic characterization of Chinese ovarian clear cell carcinoma identifies driver genes by whole exome sequencing.
    Yang Q; Zhang C; Ren Y; Yi H; Luo T; Xing F; Bai X; Cui L; Zhu L; Ouyang J; Jiang P; Fan W; Qiu J; Wang F; Xing X; Zhang Z; Zhang X; Zhang R
    Neoplasia; 2020 Sep; 22(9):399-430. PubMed ID: 32650224
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A clearer view on ovarian clear cell carcinoma.
    De Pauw A; Naert E; Van de Vijver K; Philippe T; Vandecasteele K; Denys H
    Acta Clin Belg; 2022 Aug; 77(4):792-804. PubMed ID: 34404331
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frequent PIK3CA mutations in eutopic endometrium of patients with ovarian clear cell carcinoma.
    Murakami K; Kanto A; Sakai K; Miyagawa C; Takaya H; Nakai H; Kotani Y; Nishio K; Matsumura N
    Mod Pathol; 2021 Nov; 34(11):2071-2079. PubMed ID: 34172890
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genomics to immunotherapy of ovarian clear cell carcinoma: Unique opportunities for management.
    Oda K; Hamanishi J; Matsuo K; Hasegawa K
    Gynecol Oncol; 2018 Nov; 151(2):381-389. PubMed ID: 30217369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival Following Chemotherapy in Ovarian Clear Cell Carcinoma Is Not Associated with Pathological Misclassification of Tumor Histotype.
    Takenaka M; Köbel M; Garsed DW; Fereday S; Pandey A; Etemadmoghadam D; Hendley J; Kawabata A; Noguchi D; Yanaihara N; Takahashi H; Kiyokawa T; Ikegami M; Takano H; Isonishi S; Ochiai K; Traficante N; Gadipally S; Semple T; Vassiliadis D; Amarasinghe K; Li J; Mir Arnau G; Okamoto A; Friedlander M; Bowtell DDL;
    Clin Cancer Res; 2019 Jul; 25(13):3962-3973. PubMed ID: 30967419
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted Molecular and Immunohistochemical Analyses of Endometrial Clear Cell Carcinoma Show that POLE Mutations and DNA Mismatch Repair Protein Deficiencies Are Uncommon.
    Baniak N; Fadare O; Köbel M; DeCoteau J; Parkash V; Hecht JL; Hanley KZ; Gwin K; Zheng W; Quick CM; Jarboe EA; Liang SX; Kinloch M
    Am J Surg Pathol; 2019 Apr; 43(4):531-537. PubMed ID: 30585826
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clonal lineage from normal endometrium to ovarian clear cell carcinoma through ovarian endometriosis.
    Suda K; Cruz Diaz LA; Yoshihara K; Nakaoka H; Yachida N; Motoyama T; Inoue I; Enomoto T
    Cancer Sci; 2020 Aug; 111(8):3000-3009. PubMed ID: 32473611
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.